Company: ACBM
Filing Date: 2025-07-24
Form Type: 10-K
Source: 0001640334-25-001300
Chunk: 399

Company: ACRO BIOMEDICAL CO., LTD.
Filing Date: 2025-07-24
Form: 10-K
Item: Item 6
Chunk 399
---
 Amount    Shares    Amount    Capital   compensation   Deficit  Equity (Deficit)                          Balance, December 31, 2022  -  $-   60,042,000  $60,042  $32,295,236  $(8,060,983) $(23,807,925) $486,370                                  Amortization of deferred stock compensation   -   -   -   -   -   8,060,983   -   8,060,983 Imputed interest on related party loans  -   -   -   -   3,206   -   -   3,206 Net loss  -   -   -   -   -   -   (8,807,573)  (8,807,573)                                 Balance, December 31, 2023  -   -   60,042,000   60,042   32,298,442   -   (32,615,498)  (257,014)                                 Imputed interest on related party loans  -   -   -   -   4,339   -   -   4,339 Net loss  -   -   -   -   -   -   (42,297)  (42,297)                                 Balance, December 31, 2024  -  $-   60,042,000  $60,042  $32,302,781  $-  $(32,657,795) $(294,972)

The accompanying notes are an integral part of these financial statements.

 F-5Table of Contents

ACRO BIOMEDICAL CO., LTD.

Statements of Cash Flows

  Year ended   December 31,   2024  2023        CASH FLOWS FROM OPERATING ACTIVITIES      Net loss $(42,297) $(8,807,573)Adjustments to reconcile net loss to net cash used in operating activities: